Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhaoke OphthalmologyHKSE:06622 +1.61%47 Gross Margin % is 46.91% as of Dec. 2025, which is 37% below its 10-year median of 74.72. GuruFocus rates HKSE:06622 with a GF Score™ of 47/100 and a GF Value™ of HK$2.60 (Fairly Valued). The stock has 5 warning signs investors should review. Among 738 Biotechnology companies, Zhaoke Ophthalmology ranks worse than 60.7% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Zhaoke Ophthalmology had a gross margin of 46.91% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Zhaoke Ophthalmology Gross Margin % Related Terms
Zhaoke Ophthalmology Gross Margin % Historical Data
* Premium members only.
The historical data trend for Zhaoke Ophthalmology's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06622 vs VRTX, REGN, MRNA: Gross Margin % Comparison
For the Biotechnology subindustry, Zhaoke Ophthalmology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhaoke Ophthalmology Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Zhaoke Ophthalmology's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Zhaoke Ophthalmology (HKSE:06622) has a Gross Margin % of 46.91% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Zhaoke Ophthalmology and its competitors. This is 37% below median its historical median of 74.72. Over the past decade, Zhaoke Ophthalmology's Gross Margin % has ranged from 50.19 to 75.98. According to the industry distribution chart, Zhaoke Ophthalmology ranks #448 out of 738 companies in the Biotechnology industry, placing it in the top 60.7%.
Is Zhaoke Ophthalmology's Gross Margin % too high?
Zhaoke Ophthalmology's current Gross Margin % of 46.91% is 37% below median its 10-year median of 74.72. Over the past 10 years, this metric has ranged from a low of 50.19 to a high of 75.98. The Biotechnology industry median Gross Margin % is 60.94. Zhaoke Ophthalmology's value of 46.91% is 23% below this industry median. Based on the distribution chart, Zhaoke Ophthalmology ranks #448 out of 738 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zhaoke Ophthalmology has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhaoke Ophthalmology's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhaoke Ophthalmology ranks #448 out of 738 companies for Gross Margin %. This places Zhaoke Ophthalmology in the lower half of its industry. The industry median Gross Margin % is 60.94. Zhaoke Ophthalmology's value of 46.91% is 23% below this benchmark. Historically, Zhaoke Ophthalmology's own Gross Margin % has ranged from 50.19 to 75.98 over the past decade. While the company's 10-year median is 74.72 vs. the industry median of 60.94, Zhaoke Ophthalmology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhaoke Ophthalmology's current Gross Margin % of 46.91% is 23% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Zhaoke Ophthalmology and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhaoke Ophthalmology's current Gross Margin % is 46.91%, which is 37% below median its own 10-year median of 74.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhaoke Ophthalmology stock overvalued right now?
Based on GuruFocus' analysis, Zhaoke Ophthalmology (HKSE:06622) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.60, compared to a current price of HK$2.53 — trading 2.7% below its estimated fair value. The current Gross Margin % is 46.91%, which is 37% below median its 10-year median of 74.72 and 23% below the Biotechnology industry median of 60.94. Zhaoke Ophthalmology's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Zhaoke Ophthalmology (HKSE:06622), the current Gross Margin % is 46.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhaoke Ophthalmology (HKSE:06622) Overvalued in 2026?
Based on GuruFocus' analysis, Zhaoke Ophthalmology stock appears to be undervalued.
The current stock price of HK$2.53 is trading 2.7% below its estimated GF Value™ of HK$2.60.
GuruFocus considers Zhaoke Ophthalmology to be Fairly Valued.
Key valuation signals for HKSE:06622:
Gross Margin %: 46.91% (37% below median its 10-year median of 74.72)
GF Value™: HK$2.60 vs. price of HK$2.53 (2.7% below fair value)
Industry Position: 23% below the Biotechnology median (#448 of 738)
No single metric tells the full story. See the HKSE:06622 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Chinese Mainland, South Korea, and Others, of which it generates maximum revenue from Chinese Mainland.
47GF Score
Get the complete analysis for HKSE:06622
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06622 has been successfully added to your 
